Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Previous Treatments on the Efficacy of Imetelstat in Patients with Transfusion-Dependent, ESA-Relapsed or -Refractory/-Ineligible Lower-Risk Myelodysplastic Syndromes

  • By

  • Rami S. Komrokji

  • Valeria Santini

  • Amer M. Zeidan

  • Mikkael A. Sekeres

  • Pierre Fenaux

  • Azra Raza

  • Moshe Mittelman

  • Sylvain Thépot

  • Rena Buckstein

  • Ulrich Germing

  • Yazan F. Madanat

  • María Díez-Campelo

  • David Valcárcel

  • Anna Jonášová

  • Souria Dougherty

  • Sheetal Shah

  • Qi Xia

  • Libo Sun

  • Shyamala Navada

  • Faye Feller

  • Michael R. Savona

  • Uwe Platzbecker

  • December 31, 2025

Share

Original Source(s)

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

  • by Rami S. Komrokji, Valeria Santini, Amer M. Zeidan, Mikkael A. Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, Yazan F. Madanat, María Díez-Campelo, David Valcárcel, Anna Jonášová, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Faye Feller, Michael R. Savona, Uwe Platzbecker

  • December 31, 2025

Related Content

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

Increasing Length of the Babesia Season in New England in the Climate Change Era

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • December 17, 2025

  • 4 min